Sava Technologies, a London-based medical technology innovator, has successfully closed a $36 million Series B funding round, marking a significant milestone in the development of next-generation wearable health monitors. The funding round was bolstered by a strategic partnership and exclusive sales agreement with Ascensia Diabetes Care, a global leader in diabetes management solutions. This capital injection, which brings Sava’s total funding to date to $68 million, is earmarked for the scaling of manufacturing operations and the advancement of clinical trials for a novel continuous glucose monitoring (CGM) system that promises to be less invasive than current market leaders.
The partnership with Ascensia serves as a major validation of Sava’s proprietary microsensor technology. Under the terms of the agreement, Ascensia has made a strategic equity investment in the start-up and will serve as the exclusive distributor of Sava’s CGM sensors in European markets upon regulatory approval. This move signals a significant expansion for Ascensia, which has traditionally focused on blood glucose meters and has previously partnered with Senseonics for long-term implantable sensors. By backing Sava, Ascensia is positioning itself to compete more directly in the rapidly growing wearable sensor market, currently dominated by industry titans Abbott and Dexcom.
Engineering a Less Invasive Monitoring Experience
The centerpiece of Sava’s value proposition is its "microsensor" architecture. While traditional CGM devices utilize a small filament—typically several millimeters long—that is inserted into the subcutaneous tissue to measure glucose levels in the interstitial fluid, Sava claims its sensors are approximately ten times shorter. This reduction in length is intended to minimize tissue disruption, reduce the risk of skin irritation, and eliminate the discomfort often associated with the insertion of larger sensors.
Despite the reduced size, the device is designed to maintain high levels of accuracy. The sensor measures glucose levels in the interstitial fluid just beneath the surface of the skin, providing real-time data to a connected smartphone application. A critical goal for the company is achieving regulatory approval for "non-adjunctive use." This designation would allow patients to make critical insulin dosing decisions based solely on the sensor’s readings, without the need for supplementary finger-stick blood tests for calibration or confirmation—a standard that has become the benchmark for modern CGM technology.
Industry analysts suggest that the "form factor" of CGMs remains one of the primary barriers to adoption. While current devices like the Dexcom G7 and Abbott’s FreeStyle Libre 3 have become increasingly diminutive, some users still report "compression lows"—false low-glucose readings caused by pressure on the sensor during sleep—and skin reactions to adhesives. Sava’s shorter filament and low-profile design aim to mitigate these specific pain points, potentially appealing to a broader demographic of users, including those with sensitive skin or those who find existing devices too cumbersome.
The Strategic Path to Commercialization and Clinical Trials
With the Series B funds secured, Sava is transitioning from a research-and-development phase into a rigorous clinical and commercial preparation phase. The company has announced plans to initiate a pivotal clinical trial before the end of 2026. This trial will be instrumental in gathering the safety and efficacy data required for regulatory submissions in the European Union and eventually the United States.
Sava’s immediate commercial target is the European market. The company anticipates securing a CE Mark (Conformité Européenne) within the next two years, which would clear the way for a commercial launch across EU member states. The collaboration with Ascensia is pivotal here; Ascensia’s established logistics networks, relationships with healthcare providers, and expertise in navigating European reimbursement landscapes provide Sava with a ready-made commercial infrastructure.
The timeline for Sava’s development reflects the increasing regulatory scrutiny on medical devices in Europe under the Medical Device Regulation (MDR) framework. By partnering with an established player like Ascensia, Sava mitigates the risks associated with scaling a sales force and managing the complex supply chains required for high-volume medical device production.
Diversifying the Investor Base and Financial Outlook
The $36 million Series B round saw participation from a diverse group of venture capital firms and strategic partners. In addition to Ascensia’s equity stake, the round included contributions from Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, and Pentland Ventures. The involvement of Norrsken VC, a firm focused on "impact" investing, highlights the potential for Sava’s technology to improve public health outcomes on a global scale.
The total capital raised by Sava—now standing at $68 million—reflects a resilient interest in the medtech sector, particularly in technologies that address chronic disease management. Despite a broader tightening of venture capital in some tech sectors, the diabetes care market remains a high-priority area for investors due to the staggering global prevalence of the disease and the shift toward digital health solutions.
Breaking the Duopoly: Competitive Dynamics in the CGM Market
The CGM market has long been characterized by a formidable duopoly. Abbott’s FreeStyle Libre and Dexcom’s G-series sensors currently account for the vast majority of global market share. While Medtronic also offers CGM systems integrated with its insulin pumps, and Senseonics provides an implantable option, the "wearable patch" segment is where the most intense competition lies.
Sava’s entry into this space is timed to capitalize on a growing demand for choice. In a statement following the funding announcement, Sava noted that while the market is expanding, the limited number of manufacturers has led to a situation where demand occasionally outpaces the options available to distributors, clinicians, and patients. By introducing a device with a different mechanical profile (the shorter microsensor), Sava is betting that it can carve out a niche among users who are dissatisfied with the current industry standards.
Furthermore, Ascensia’s shift toward Sava represents a noteworthy change in its internal strategy. While Ascensia continues to support Senseonics’ Eversense—a sensor that can stay in the body for up to a year—the partnership with Sava allows Ascensia to offer a more traditional, short-term wearable that does not require a physician-led insertion procedure. This "two-pronged" approach allows Ascensia to cover both the long-term implantable and the short-term wearable segments of the market.
Beyond Glucose: The Future of Multi-Biomarker Monitoring
While the initial focus of Sava’s technology is glucose monitoring for diabetes management, the company’s vision extends into the realm of "biowearables." The microsensor platform is being designed with the capability to expand into other biomarkers. Potential future applications include the monitoring of lactate (for athletic performance and sepsis detection), ketones (for metabolic health and diabetic ketoacidosis prevention), and even certain medications or hormones.
Ascensia has acknowledged this long-term potential, noting that the microsensor technology could eventually serve as a comprehensive health monitoring hub. The move toward multi-biomarker sensing is a major trend in the industry. Abbott, for instance, recently launched its "Lingo" sensor in certain markets, targeting non-diabetic consumers interested in metabolic health. By developing a platform that can be adapted for various analytes, Sava is positioning itself not just as a diabetes company, but as a foundational player in the emerging "quantified self" and preventative medicine sectors.
Global Context: The Growing Burden of Diabetes
The urgency behind Sava’s development is underscored by global health statistics. According to the International Diabetes Federation (IDF), approximately 537 million adults were living with diabetes in 2021, a number projected to rise to 783 million by 2045. Despite the proven benefits of CGM in improving glycemic control and reducing long-term complications, only a small fraction of these individuals currently use the technology. Sava estimates that only about 12 million people globally use CGMs today.
The barriers to wider adoption include cost, lack of access in developing regions, and the invasive nature of current devices. If Sava can successfully scale its manufacturing to lower costs and prove that its microsensors are more comfortable for daily wear, it could play a vital role in expanding CGM access to Type 2 patients and those in earlier stages of the disease who are currently managed through less frequent blood glucose monitoring.
Implications for the Medtech Industry
The success of Sava’s funding round and its partnership with Ascensia suggests a maturing of the European medtech ecosystem. It demonstrates that start-ups can still secure significant capital for hardware-intensive medical devices if they offer a clear technological advantage and a strategic path to market.
For the broader medtech industry, the Sava-Ascensia deal highlights the importance of strategic alliances. For large, established firms, these partnerships provide a way to stay at the cutting edge of innovation without the overhead of internal R&D for every new technology. For start-ups, they provide the "commercial oxygen" needed to survive the transition from a laboratory concept to a regulated medical product.
As Sava moves into its pivotal trials, the medical community will be watching closely to see if the theoretical benefits of microsensors translate into real-world clinical advantages. If successful, the partnership between Sava and Ascensia could not only provide a new tool for diabetes management but also set a new standard for how we interact with wearable health technology in the years to come. The next two years will be a defining period for the company as it seeks to navigate the final regulatory hurdles and bring its vision of "painless" monitoring to the millions of patients awaiting more flexible healthcare solutions.
